As equity markets globally saw a sharp correction this year, PharmEasy shelved its IPO plans. In a candid interview, CEO Siddharth Shah opened up about the company’s road ahead, including profitability plans, valuation mismatch, business strategy, and rumours about putting Thyrocare up for sale.
Read More Tech-Prime-Economic Times